Great progress in the treatment of patients with chronic myeloid leukemia has been made with the introduction of tyrosine kinase inhibitors (TKIs), which is the first targeted molecular therapy since it is a competitive inhibitor of the BCR::ABL tyrosine kinase protein. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.